GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » PB Ratio

Halozyme Therapeutics (Halozyme Therapeutics) PB Ratio : 57.88 (As of Apr. 30, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-30), Halozyme Therapeutics's share price is $38.26. Halozyme Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.66. Hence, Halozyme Therapeutics's PB Ratio of today is 57.88.

The historical rank and industry rank for Halozyme Therapeutics's PB Ratio or its related term are showing as below:

HALO' s PB Ratio Range Over the Past 10 Years
Min: 8.24   Med: 32.53   Max: 157.01
Current: 57.97

During the past 13 years, Halozyme Therapeutics's highest PB Ratio was 157.01. The lowest was 8.24. And the median was 32.53.

HALO's PB Ratio is ranked worse than
98.93% of 1308 companies
in the Biotechnology industry
Industry Median: 2.435 vs HALO: 57.97

During the past 12 months, Halozyme Therapeutics's average Book Value Per Share Growth Rate was -47.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -16.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -7.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Halozyme Therapeutics was 234.20% per year. The lowest was -39.30% per year. And the median was -5.90% per year.

Back to Basics: PB Ratio


Halozyme Therapeutics PB Ratio Historical Data

The historical data trend for Halozyme Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics PB Ratio Chart

Halozyme Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.42 38.17 28.08 45.30 55.92

Halozyme Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.30 76.38 31.50 20.24 55.92

Competitive Comparison of Halozyme Therapeutics's PB Ratio

For the Biotechnology subindustry, Halozyme Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's PB Ratio falls into.



Halozyme Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Halozyme Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=38.26/0.661
=57.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Halozyme Therapeutics  (NAS:HALO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Halozyme Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Halozyme Therapeutics (Halozyme Therapeutics) Business Description

Traded in Other Exchanges
Address
12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Executives
Michael J. Labarre officer: SVP, Chief Technical Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley director, officer: President and CEO C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Nicole Labrosse officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Akiko Moni Miyashita director 20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari director 235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley director 1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun officer: SVP, Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda officer: SVP, General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey officer: SVP, Chief Commerical Officer C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121